Rallybio Corp
No enriched coverage for $RLYB in the last 7 days.
No SEC Form 4 filings for $RLYB in the last 30 days.
See all $RLYB insider activity →Rallybio's CFO Jonathan Lieber will transition to a part-time role while retaining his duties and authority, effective September 15, 2026. He will receive a base salary of $420,000 but is ineligible for annual bonuses during this period. The company did not disclose reasons or replacement plans.
Rallybio Corp (RLYB) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 8, 2026, Rallybio Corporation (Rallybio) announced that Jonathan Lieber, Rallybio’s Chief Financial Officer,
RallyBio, which abandoned a reverse merger with Candid Therapeutics after the plan dissolved, announced a new reverse merger with Avenzo Therapeutics, according to the deal announced Monday. The combined company will trade on Nasdaq as AVZO, raise $215 million, and is expected to close by year-end. RallyBio has faced layoffs and disappointing results since going public in 2021.
Recent RLYB coverage spans corporate actions, mergers & acquisitions and market movers.
Change in CFO employment status may affect perception of financial leadership stability.
The compensation change may affect investor perception of management stability and merger execution risk.
RLYB faces renewed corporate-action risk/reward as it attempts to re-route capital markets via a fresh reverse merger.
M&A deal terms and committed funding create a clear catalyst for valuation re-rating and deal-spread trading.
Rallybio's recent funding boost and extended cash runway suggest improved financial health, potentially supporting stock appreciation in the near term.
AlphAI scores every news story that mentions RLYB with an AI model for sentiment and relevance, and aggregates insider trades from Rallybio Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
Rallybio's CFO Jonathan Lieber will transition to a part-time role while retaining his duties and authority, effective September 15, 2026. He will receive a base salary of $420,000 but is ineligible for annual bonuses during this period. The company did not disclose reasons or replacement plans.
1 min readRallybio Corp (RLYB) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 8, 2026, Rallybio Corporation (Rallybio) announced that Jonathan Lieber, Rallybio’s Chief Financial Officer,
1 min readRallyBio, which abandoned a reverse merger with Candid Therapeutics after the plan dissolved, announced a new reverse merger with Avenzo Therapeutics, according to the deal announced Monday. The combined company will trade on Nasdaq as AVZO, raise $215 million, and is expected to close by year-end. RallyBio has faced layoffs and disappointing results since going public in 2021.
4 min readTurn Therapeutics (TTRX) rose over 20% after interim Phase 2 results for GX-03 in atopic dermatitis, with 92.6% achieving EASI-50 at 4 weeks. Conexeu (CNXU) gained ~19% on preclinical B.R.E.A.S.T. bioprinting progress. Rallybio (RLYB) jumped on plans to acquire Avenzo via a $215M investment. LIXTE (LIXT) surged on an AI energy pivot; Quanterix (QTRX) rose on insider SEC filing.
7 min readRallybio receives $7.5 million upfront equity and is eligible for $17.5 million in future milestone payments. The cash runway is now extended into mid-2027 following the asset sale. From tariffs to inflation, macro risks are rising-Matt Maley reveals how he's trading it all, live this Wednesday ...
2 min read
